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Electronic Supplementary Information
Table S1 PDB codes and ligand/drug and myristic acids binding sites for selected HSA 
crystal structures.
PDB 
code
Ligand/drug name Ligand/drug 
binding sitea
Myristic acid binding sitea
1HA2 S-Warfarin IIA FA1, FA2, FA3, FA4, FA5, FA6
1HK1 L-Thyroxine IIA IIIA IIIB -
1O9X Hemin IB FA2, FA3, FA4, FA5, FA6, FA7
2BXB Oxyphenbutazone IIA -
2BXD R-Warfarin IIA -
2BXF Diazepam IIIA -
2BXI Azapropazone IB IIA FA2, FA3, FA4, FA5, FA6
2BXK Indomethacin, 
Azapropazone
IIA FA1, FA2, FA3, FA4, FA5, FA6
2VUE 4Z,15E-Bilirubin-IXalpha IB -
2VUF Fusidic acid IB IIIB -
2XVU Dansyl-L-Asparagine IIA IIIA -
3CX9  Lysophosphatidylethanolamine IIA FA2, FA3, FA4, FA5, FA6
4L9K Camptothecin IB -
4L9Q Tenoposide IB -
4LA0 R-Bicalutamide IB -
1E7G - - FA1, FA2x2, FA3, FA4, FA5, 
FA6, FA7
a Binding sites notations are taken from Ref. 29 of the main text.
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Table S2 Overlapping of proposed phycocyanobilin binding sites (IB and IIA) and binding 
sites for ligands/drugs on 14 HSA crystal structures found in the PDB.
PDB 
code
Ligand/drug name Binding site IB 
on HSA
Binding site IIA 
on HSA
1HA2 S-Warfarin - R222, H242, R257
1HK1 L-Thyroxine - K195, K199, W214, R218, 
R222, H242, R257
1O9X Hemin R114, R117, Y138, Y161 -
2BXB Oxyphenbutazone - K195, Q196, K199, W214, 
R218, R222, H242, R257
2BXD R-Warfarin - K199, R222, H242, R257
2BXI Azapropazone R117, Y138, R186 K199, R218, R222, H242, 
R257
Indomethacin - K199, W214, R2182BXK
Azapropazone - K199, R218, R222, H242, 
R257
2VUE 4Z,15E-Bilirubin-
IXalpha
R117, F134, Y138, R145, 
Y161, R186
-
2VUF Fusidic acid R117, F134, Y138, Y161, 
R186
-
2XVU Dansyl-L-Asparagine - K199, W214, R222, H242, 
R257
3CX9 Lysophosphatidyl-
ethanolamine
- Q196, K199, W214, R222, 
H242, R257
4L9K Camptothecin R117, Y138, Y161, R186 -
4L9Q Tenoposide R117, F134, Y138, E141, 
Y161, D183, R186,
-
4LA0 R-Bicalutamide R117, F134,Y138, E141 -
Table S3 Re-docking simulations RMSD values and phycocyanobilin binding energies for 16 
HSA crystal structures extracted from PDB.
PDB 
code
Ligand/drug 
binding site
Re-dock 
RMSD value
PCB 
binding site
Binding energy 
(kcal/mol)
IIA 10.51HA2 IIA 0.2243
IB 10.8
IIA 9.91HK1 IIA
IIIB
IIIA
0.6964 IIA
0.2995 IIIB
0.8722 IIIA IB 8.7
IIA 9.71O9X IB 0.5652
IB 10.5
IIA 8.52BXB IIA 0.3047
IB 8.8
IIA 8.72BXD IIA 0.0000
IB 9.7
IIA 9.12BXF IIIA 0.2091
IB 8.8
IIA 9.32BXI IB
IIA
0.5567 IB
0.8713 IIA IB 10.5
IIA 10.22BXK IIA IMNa
IIA AZQa
0.1384 IMNa 
0.9941 AZQa IB 9.7
IIA 8.62VUE IB 0.3310
IB 8.4
IIA 8.52VUF IB
IIIB
0.3017 IB
2.2162 IIIB IB 9.1
IIA 9.52XVU IIA
IIIA
0.3467 IIA
0.3239IIIB IB 9.3
IIA 9.53CX9 IIA 0.5311
IB 9.5
IIA 8.94L9K IB 0.2581
IB 10.2
IIA 9.64L9Q IB 0.2293
IB 10.3
IIA 9.24LA0 IB 3.8581
IB 10.3
IIA 9.31E7G - -
IB 10.7
a IMN - Indomethacin; AZQ - Azapropazone
Table S4 Phycocyanobilin binding energies for 6 HSA crystal structures with myristic acids 
extracted from PDB.
PDB code Myristic acid 
binding site
PCB 
binding site
Binding energy 
(kcal/mol)
IIA 10.51HA2 FA1, FA2, FA3, 
FA4, FA5, FA6 IB -
IIA 10.41O9X FA2, FA3, FA4, 
FA5, FA6, FA7 IB 10.5
IIA 9.32BXI FA2, FA3, FA4, 
FA5, FA6 IB 10.6
IIA 10.32BXK FA1, FA2, FA3, 
FA4, FA5, FA6 IB -
IIA 9.53CX9 FA2, FA3, FA4, 
FA5, FA6 IB 9.5
IIA 8.21E7G FA1, FA2x2, 
FA3, FA4, FA5, 
FA6, FA7 IB -
Table S5 Phycocyanobilin binding energies for 14 HSA crystal structures with ligand present 
at the same binding site on protein.
PDB 
code
Ligand/Myristic 
acid binding site
PCB 
binding site
Binding energy 
(kcal/mol)
1HA2 IIA, FA1, FA2, FA3, 
FA4, FA5, FA6
IIA -
1HK1 IIA IIA -
1O9X IB, FA2, FA3, FA4, 
FA5, FA6, FA7
IB -
2BXB IIA IIA -
2BXD IIA IIA -
2BXI IB, IIA, FA2, FA3, 
FA4, FA5, FA6
IIA
IB
8.6
-
2BXK IIA IMN, IIA AZQ IIA 9.0
2VUE IB IB -
2VUF IB, IIIB IB -
2XVU IIA, IIIA IIA -
3CX9 IIA, FA2, FA3, FA4, 
FA5, FA6
IIA 9.0
4L9K IB IB -
4L9Q IB IB -
4LA0 IB IB -
1HA2 IIA 1HK1 IIA
109X IB 2BXB IIA
2BXD IIA 2BXI IB
2BXI IIA 2BXK AZQ IIA
2BXK IMN IIA 2VUE IB
2VUF IB 2XVU IIA
3CX9 IIA 4L9K IB
4L9Q IB 4LA0 IB
Figure S1 Amino acid residues within 3.5Å from the ligand/drug binding site (IIA or IB) for 
ligands/drugs from selected HSA crystal structures.
Figure S2 Re-docked (yellow) and crystallographic (red) positions for: (A) 2VUE (RMSD 
value 0.3310) structure and (B) 4LA0 (RMSD value 3.8581) structure; (C) Superimposition 
of docked phycocyanobilin (purple) and cristalographically found 4Z,15E-bilirubin-IXα 
(yellow) in PDB 2VUE structure.
 Figure S3 (A) Myristic acid (red) at the FA1 site and docked phycocyanobilin (purple) 
towards the cleft binding site; (B) Myristic acid (red) at the FA7 site and docked 
phycocyanobilin (purple) in the IIA binding site.
Figure S4 Ligand(s) (orange) and docked phycocyanobilin (purple) in the IIA binding site, 
PDB codes: 2BXK (A) and 3CX9 (B).
Figure S5 Fluorescence quenching based plots (from data for determination of binding 
constants and number of binding sites of HSA-phycocyanobilin complex at different 
temperatures). Error bars represent standard deviation.
Figure S6 Plot based on Van't Hoff equation for determination of thermodynamic parameters 
of HSA-phycocyanobilin system. Error bars represent standard deviation.
Figure S7 Fluorescence enhancement based plots for determination of binding constant of 
HSA-phycocyanobilin complex. Error bars represent standard deviation.
Figure S8 Quenching of HSA-bilirubin complex (2 μM both) by warfarin (0, 2, 4, 6, 8 and 
20 μM, for curves a to f, respectively) (excitation wavelength 460 nm). Dot line curve: 2 μM 
bilirubin, dash line curve: 2 μM HSA in presence of 20 μM warfarin.
Figure S9 Quenching of HSA-warfarin complex (0.25 μM both) by bilirubin (0, 0.125, 0.25, 
0.375, and 0.5, for curves a to e, respectively) using synchronous fluorescence spectroscopy, 
Δλ 64 nm. Dash line curve: 0.25 μM HSA. Dot line curve: 0.25 μM warfarin. Dash-dot line 
curve represents 0.25 μM HSA in presence of 0.5 μM bilirubin.
Figure S10 Quenching of HSA-bilirubin complex (2 μM both) by hemin (0, 1, 2, 3, 4, and 5 
μM, for curves a to f, respectively) (excitation wavelength 460 nm). Dot line curve: 2 μM 
bilirubin, dash line curve: 2 μM HSA in presence of 5 μM hemin.
